DECKERS OUTDOOR CORP annual report, Q4 FY2002

Business Context and Reporting Period

Company: Deckers Outdoor Corp.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Business Overview: Deckers designs and markets innovative footwear under three primary brands: Teva (sports sandals/outdoor), Simple (casual lifestyle), and Ugg (sheepskin boots). In November 2002, the Company acquired all worldwide Teva assets (trademarks, patents, and catalog/internet business) from its former licensor, transitioning from a licensing model to full ownership.

Key Financial Metrics

Metric 2002 2001
Net Sales $99.1 million $91.5 million
Gross Profit $41.5 million $38.6 million
Gross Margin 41.9% 42.2%
Operating Income $3.3 million $2.3 million
Net Income (Loss) $(7.4) million $1.6 million
Diluted EPS (Loss) $(0.75) $0.17
Cash and Equivalents $3.9 million $16.7 million
Total Debt $39.0 million $0.4 million
Working Capital $22.5 million $41.4 million

Material Changes vs. Prior Period

  • Revenue Growth: Net sales increased 8.4% to $99.1 million, driven by a 22.4% surge in Ugg sales and a 5.9% increase in Teva wholesale sales. Simple sales declined 6.4% due to international market weakness.
  • Net Loss Driver: The reported net loss of $7.4 million was primarily caused by a non-cash goodwill impairment charge of $9.0 million (net of tax) resulting from the adoption of SFAS 142. Excluding this charge, the Company reported net income of $1.6 million.
  • Debt Increase: Total debt jumped from $0.4 million to $39.0 million to finance the $62.3 million acquisition of Teva assets. Financing included a $7 million term loan, $14 million in subordinated debt, and $13 million in seller notes.
  • Litigation Settlement: The Company settled a long-standing Montana lawsuit for $4.0 million, recording $3.2 million in charges during 2002.
  • Inventory Management: Total inventory decreased 7% to $17.1 million, reflecting a reduction in Teva inventory despite growth in Ugg inventory.

Guidance, Outlook, and Risks

2003 Outlook: Management expects 2003 net sales to range from $101 million to $106 million, with diluted earnings per share between $0.41 and $0.46. The Company anticipates the Teva acquisition will be accretive to 2003 earnings by approximately $1 million due to the elimination of royalty payments.

Key Risks and Contingencies:

  • Foreign Manufacturing: Virtually all products are manufactured overseas (primarily China), exposing the Company to supply chain disruptions, currency fluctuations, and import duties.
  • Anti-Dumping Duties: A $500,000 reserve exists for potential European anti-dumping levies on past imports, though duties on future imports were repealed in late 2002.
  • Seasonality: Sales are highly seasonal, with Teva peaking in Q1/Q2 and Ugg in Q4. Weather conditions significantly impact demand.
  • Brand Dependence: Success relies heavily on the strength of the Teva, Simple, and Ugg brands and the ability to anticipate fashion trends.

Investor Verification Checklist

  • Goodwill Impairment: Verify the sustainability of the $9.0 million non-cash charge and the remaining goodwill balance of $18.0 million.
  • Debt Service: Assess the Company's ability to service $39 million in debt, including high-interest subordinated notes (16.75%) and seller notes, given the reduced cash position.
  • Teva Integration: Monitor the performance of the newly acquired Teva catalog/internet business and the elimination of royalty expenses.
  • Simple Brand Turnaround: Evaluate strategies to reverse the decline in Simple sales and reduce closeout inventory.
  • Liquidity Position: Confirm that the $14.4 million remaining credit availability under the revolving facility is sufficient for working capital needs.